Repository logo
 
Publication

The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report

2023-08-17Journal article Open access
Simple item page
dc.contributor.authorGrigorian-Shamagian, Lilian
dc.contributor.authorCoca, Antonio
dc.contributor.authorMorais, Joao
dc.contributor.authorPerez-Martinez, Pablo
dc.contributor.authorBarragan, Adriana
dc.contributor.authorBarrientos, Ana Isabel
dc.contributor.authore Silva, Alexandre Amaral
dc.contributor.authorSugraliyev, Akhmetzhan
dc.contributor.authorParkhomenko, Alexander
dc.contributor.authorLiprandi, Álvaro Sosa
dc.contributor.authorParapid, Biljana
dc.contributor.authorOlivares, Carlos
dc.contributor.authorNegretti, Carlos Ignacio Ponte
dc.contributor.authorQuesada, Daniel
dc.contributor.authorKosevic, Dragana
dc.contributor.authorGastelum, Edith Ruiz
dc.contributor.authorLópez, Emilio Samael Peralta
dc.contributor.authorAraujo, Francisco
dc.contributor.authorPadilla Padilla, Francisco Gerardo
dc.contributor.authorKrzesinski, François
dc.contributor.authorAlhaddad, Imad
dc.contributor.authorFernandez, Jose Alejandro Chavez
dc.contributor.authorGonzalez-Juanatey, Jose R.
dc.contributor.authorArnaout, M. Samir
dc.contributor.authorCastellanos, Mar
dc.contributor.authorMendez, Maxima
dc.contributor.authorAcevedo, Monica
dc.contributor.authorKoval, Olena
dc.contributor.authorJorge, Pablo
dc.contributor.authorZelveian, Parounak
dc.contributor.authorKreutz, Reinhold
dc.contributor.authorTseluyko, Vira
dc.date.accessioned2023-11-29T15:54:18Z
dc.date.available2023-11-29T15:54:18Z
dc.date.issued2023-08-17
dc.description.abstractAlthough the cardiovascular (CV) polypill concept is not new and several guidelines state that a CV polypill should be considered an integral part of a comprehensive CV disease (CVD) prevention strategy, there are still some barriers to its implementation in the real-world setting, mainly in secondary CV prevention. As the CNIC-polypill is the only one approved for secondary CV prevention in patients with atherosclerotic CVD in 27 countries worldwide, a panel of four discussants and 30 participants from 18 countries conveyed in a virtual meeting on April 21, 2022, to discuss key clinical questions regarding the practical use of the CNIC-Polypill and barriers to its implementation. Data presented showed that, although the use of the CV polypill is not explicitly mentioned in the current 2021 European Society of Cardiology guidelines on CVD prevention, it may be used in any patient for secondary CVD prevention tolerating all their components to improve outcomes through different aspects. The favourable results of the Secondary Prevention of Cardiovascular Disease in the Elderly (SECURE) trial now reinforce this recommendation. The panellists presented algorithms on how to switch from any baseline regimen when starting treatment with the CNIC-polypill in different situations, including patients with hypertension, dyslipidaemia, and a previous CV event; at discharge after a cardiovascular event; in chronic ischemic conditions; and in cases of polypharmacy. The panellists and expert discussants did agree that available studies conducted so far with the CNIC-polypill demonstrate that it is as efficacious as the monocomponents, equipotent drugs, or other therapies; reduces the risk of experiencing recurrent major CV events; improves medication adherence; reduces health care costs and resources compared to patients treated with loose drugs; and the patients prefer it over the multipill strategy. In conclusion, the data presented by the participants provided the evidence behind the use of the CNIC-polypill to help fulfil the goal of encouraging its adoption by physicians.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationGrigorian-Shamagian, L., Coca, A., Morais, J. et al. The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report. BMC Proc 17 (Suppl 8), 20 (2023). https://doi.org/10.1186/s12919-023-00268-9pt_PT
dc.identifier.doihttps://doi.org/10.1186/s12919-023-00268-9pt_PT
dc.identifier.eissn1753-6561
dc.identifier.urihttp://hdl.handle.net/10400.8/8982
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBMCpt_PT
dc.relation.ispartofseries20;
dc.relation.publisherversionhttps://bmcproc.biomedcentral.com/articles/10.1186/s12919-023-00268-9pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectPolypillpt_PT
dc.subjectFixed-dose combinationpt_PT
dc.subjectSecondary preventionpt_PT
dc.subjectCardiovascular diseasept_PT
dc.subjectCerebrovascular diseasept_PT
dc.titleThe use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting reportpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage17pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleBMC Proceedingspt_PT
oaire.citation.volume17pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s12919-023-00268-9 (1).pdf
Size:
2.49 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.32 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ciTechCare - Artigos